In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...
The funding includes an initial tranche of $7.5 million in equity and technical support, and the biotech and the foundation will form a joint steering committee.
Enhertu Benefit in HER2-Low Breast Cancer That's Also HR-Negative Supported by Longer Follow-Up Data
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.
NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.
The firm will use the funds to test its NaPi2b-targeted ADC in earlier lines of treatment and across tumor types, and another ADC in 5T4-expressing solid tumors.
The firm amended the terms of a deal with Pfizer and submitted results from the BREAKWATER trial of Braftovi, Erbitux, and chemo against chemo alone.
The trial, performed at Radboud University Medical Center, will test TGW211, which involves a trigger designed to limit off-target effects of the radioactive material.
The cell and gene therapy manufacturing company will provide services to advance early-stage translational R&D at Mass General Brigham.
The firm continues to seek needed funds to launch a Phase I/II trial of ELP-02 for this extremely rare form of ...
Two recent studies identified gene knockouts that may make CAR T-cell therapy more effective, but the next step is applying the hypotheses in humans.
The company is studying the mRNA tumor-associated antigen vaccine as a monotherapy and in combination with Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback